All In Biotech

Drug Trial Radar · NCT06841354

A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

A Phase 3, Randomized, Open-label Study Comparing Efficacy and Safety of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as a Monotherapy and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With Previously Untreated Locally Recurrent Unresectable or Metastatic Triple-Negative Breast Cancer Expressing PD-L1 at CPS Less Than 10 (TroFuse-011)

Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 1,000 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

1,000

Planned (sponsor's estimate)

Start

Mar 16, 2025

Primary completion

May 18, 2030

Study completion May 18, 2030

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Feb 24, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Researchers want to know if sacituzumab tirumotecan given alone or with pembrolizumab can treat triple negative breast cancer (TNBC). The main goal of this study is to learn if people treated with sacituzumab tirumotecan alone or with pembrolizumab live longer overall or without the cancer growing or spreading compared to people treated with chemotherapy.

Conditions

  • Triple Negative Breast Neoplasms

Interventions

  • Sacituzumab tirumotecanBiological

    IV Infusion

  • PembrolizumabBiological

    IV Infusion

  • Rescue MedicationDrug

    Participants receive the following pre-medications before sacituzumab tirumotecan infusion: Histamine-1 (H1) receptor agonist, histamine-2 (H2) receptor antagonist, acetaminophen or equivalent, dexamethasone or equivalent infusion. Participants are also recommended to receive prophylactic steroid mouthwash (dexamethasone or equivalent).

  • PaclitaxelDrug

    IV Infusion

  • Nab-paclitaxelDrug

    IV Infusion

  • GemcitabineDrug

    IV Infusion

  • CarboplatinDrug

    IV Infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-Free Survival (PFS) (sac-TMT versus treatment of physician's choice (TPC); sac-TMT plus pembrolizumab versus TPC)Time frame: Up to ~39 months
  2. Overall Survival (OS) (sac-TMT versus TPC)Time frame: Up to ~61 months

Locations

285 sites in 35 countries. Site status is shown where the registry gives one.

  • USA Mitchell Cancer Institute ( Site 0090)

    Mobile, Alabama · Recruiting

  • Ironwood Cancer & Research Centers ( Site 0036)

    Chandler, Arizona · Recruiting

  • City of Hope ( Site 0097)

    Duarte, California · Recruiting

  • City of Hope Lennar Foundation Cancer Center ( Site 0099)

    Irvine, California · Recruiting

  • UCLA Department of Medicine - Hematology & Oncology ( Site 0047)

    Los Angeles, California · Recruiting

  • UCSF Helen Diller Family Comprehensive Cancer Center ( Site 0016)

    San Francisco, California · Recruiting

  • Yale New Haven Hospital ( Site 0001)

    New Haven, Connecticut · Completed

  • Washington Hospital Center ( Site 0098)

    Washington D.C., District of Columbia · Recruiting

  • AdventHealth Medical Group Oncology and Hematology at Altamonte ( Site 0007)

    Altamonte Springs, Florida · Recruiting

  • Orlando Health Cancer Institute ( Site 0012)

    Orlando, Florida · Recruiting

  • Florida Cancer Specialists - East ( Site 7000)

    West Palm Beach, Florida · Recruiting

  • University Cancer & Blood Center, LLC ( Site 0023)

    Athens, Georgia · Recruiting

  • St. Luke's Cancer Institute: Boise ( Site 0037)

    Boise, Idaho · Recruiting

  • University of Illinois Cancer Center ( Site 0044)

    Chicago, Illinois · Recruiting

  • MedStar Franklin Square Medical Center ( Site 0031)

    Baltimore, Maryland · Recruiting

  • MedStar Good Samaritan Hospital ( Site 0079)

    Baltimore, Maryland · Recruiting

  • MedStar Southern Maryland Hospital Center ( Site 0100)

    Clinton, Maryland · Recruiting

  • MedStar Montgomery Medical Center ( Site 0078)

    Olney, Maryland · Recruiting

  • Holy Cross Hospital ( Site 0091)

    Silver Spring, Maryland · Recruiting

  • Cancer & Hematology Centers of Western Michigan ( Site 0026)

    Grand Rapids, Michigan · Recruiting

  • Allina Health Cancer Institute ( Site 0069)

    Minneapolis, Minnesota · Completed

  • Hattiesburg Clinic Hematology/Oncology ( Site 0104)

    Hattiesburg, Mississippi · Recruiting

  • Comprehensive Cancer Centers of Nevada ( Site 0015)

    Las Vegas, Nevada · Recruiting

  • Renown Regional Medical Center ( Site 0005)

    Reno, Nevada · Recruiting

  • John Theurer Cancer Center at Hackensack University Medical Center ( Site 0082)

    Hackensack, New Jersey · Recruiting

  • New Mexico Oncology Hematology Consultants Ltd. ( Site 0019)

    Albuquerque, New Mexico · Recruiting

  • Perlmutter Cancer Center at NYU Langone Hospital - Long Island ( Site 0073)

    Mineola, New York · Recruiting

  • Laura and Isaac Perlmutter Cancer Center ( Site 0003)

    New York, New York · Recruiting

  • Rex Hematology Oncology Associates - Garner ( Site 0071)

    Garner, North Carolina · Completed

  • SCRI Oncology Partners ( Site 7004)

    Nashville, Tennessee · Recruiting

  • Tennessee Oncology ( Site 0018)

    Nashville, Tennessee · Recruiting

  • Texas Oncology - DFW ( Site 8007)

    Dallas, Texas · Recruiting

  • Texas Oncology - West Texas ( Site 8004)

    El Paso, Texas · Recruiting

  • Kelsey-Seybold Clinic - North Houston Campus ( Site 0096)

    Houston, Texas · Recruiting

  • Kelsey-Seybold Clinic ( Site 0040)

    Houston, Texas · Recruiting

  • Texas Oncology - San Antonio ( Site 8001)

    San Antonio, Texas · Recruiting

  • University of Utah, Huntsman Cancer Institute ( Site 0056)

    Salt Lake City, Utah · Recruiting

  • Virginia Oncology Associates (VOA) ( Site 8002)

    Norfolk, Virginia · Recruiting

  • Fred Hutchinson Cancer Center ( Site 0042)

    Seattle, Washington · Recruiting

  • Fundacion Centro Oncologico de Integración Regional ( Site 2400)

    Mendoza, Argentina · Recruiting

Showing 40 of 285 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.